GILD · News · 20260804N
Acquisition-Related R&D Charges
GILEAD SCIENCES, INC. · 2026-08-04 · Importance 96 · Surprise 100 · In source text
Gilead swung to a second-quarter net loss of approximately $10.5 billion, compared with net income of $2.01 per diluted share in the year-ago quarter. The loss was primarily driven by acquired in-process research and development expenses associated with recent acquisitions, including a substantial impairment related to a discontinued non-small-cell lung cancer program. Adjusted diluted loss was reported at $6.75 per share, and the company forecast a full-year 2026 adjusted loss of $0.30 to $0.65 per share.
Key facts
- Gilead reported a net loss of $10.5 billion in Q2 2026 primarily due to acquired IPR&D and other charges. source
- Gilead swung to a quarterly loss driven by acquisition-related research and development charges, according to the earnings call highlights. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | negative | realized | — | Gilead reported a net loss of $10.5 billion in Q2 2026 primarily due to acquired IPR&D and other charges. |